HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
BR96-doxorubicin immunoconjugate
a chimeric monoclonal antibody, BR96 & doxorubicin immunoconjugate developed for the treatment of tumors that express Lewis(y)-related antigens
Also Known As:
BMS 182248; BMS-182248; SNG-15
Networked:
3
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Amino Acids, Peptides, and Proteins: 1
Proteins: 484843
Blood Proteins: 12459
Serum Globulins: 553
Immunoglobulins: 30480
Antibodies: 133716
Monoclonal Antibodies: 56412
BR96-doxorubicin immunoconjugate: 3
Immunoproteins: 43
Immunoglobulins: 30480
Antibodies: 133716
Monoclonal Antibodies: 56412
BR96-doxorubicin immunoconjugate: 3
Globulins: 3062
Serum Globulins: 553
Immunoglobulins: 30480
Antibodies: 133716
Monoclonal Antibodies: 56412
BR96-doxorubicin immunoconjugate: 3
Organic Chemicals: 133
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Polycyclic Aromatic Hydrocarbons: 2020
Naphthacenes
Anthracyclines: 9423
Daunorubicin: 2641
Doxorubicin: 35390
BR96-doxorubicin immunoconjugate: 3
Polycyclic Compounds: 6
Polycyclic Aromatic Hydrocarbons: 2020
Naphthacenes
Anthracyclines: 9423
Daunorubicin: 2641
Doxorubicin: 35390
BR96-doxorubicin immunoconjugate: 3
Carbohydrates: 22023
Glycosides: 2119
Aminoglycosides: 5131
Anthracyclines: 9423
Daunorubicin: 2641
Doxorubicin: 35390
BR96-doxorubicin immunoconjugate: 3
Related Diseases
1.
Neoplasms (Cancer)
01/01/1997 - "
The purpose of this study was to evaluate the biodistribution of DOX after BMS 182248 administration to tumor-bearing mice and to evaluate the ability of BMS 182248 to target DOX to tumors.
"
01/01/1997 - "
BMS 182248 effectively delivered DOX to L2987 xenografts implanted in athymic mice and produced higher and more prolonged tumor concentrations of free DOX than the administration of DOX alone.
"
01/01/1997 - "
As a result of this retention, the tumor concentrations of free DOX after BMS 182248 administration exceeded those produced by i.v. administration of DOX at the same dose, a finding consistent with the greater antitumor activity of BMS 182248 relative to DOX.
"
01/01/1997 - "
For this evaluation, L2987-implanted mice were given BMS 182248 (5 mg DOX/kg; three doses 4 days apart) and the levels of both conjugate-bound and free DOX in plasma, tumor, liver and heart were determined.
"
01/01/1997 - "
This suggested that, in contrast to normal tissues, tumor tissue retention of BMS 182248 by antigen-promoted binding had occurred and that kinetics of free DOX in the tumors were controlled by the rate of release of DOX from tumor-associated BMS 182248.
"
2.
Cardiotoxicity
09/01/1994 - "
No deaths or cardiotoxicity occurred in rats given 508 or 1,200 mg/m2 BMS-182248.
"
09/01/1994 - "
All changes observed with BMS-182248 were considered primarily due to the effects of doxorubicin and were substantially less severe (most notably cardiotoxicity) compared to those produced by an equivalent amount of doxorubicin.
"
09/01/1994 - "
With BMS-182248, death from glomerulonephropathy and cardiotoxicity occurred in only 4 of 20 rats given 2,550 mg/m2 (74 mg/m2 doxorubicin equivalent).
"
3.
Breast Neoplasms (Breast Cancer)
02/01/1999 - "
The BR96-doxorubicin immunoconjugate has limited clinical antitumor activity in metastatic breast cancer.
"
4.
Adenocarcinoma of Lung
01/01/1997 - "
The chimeric BR96-doxorubicin (DOX) immunoconjugate, BMS 182248, has induced remissions and cures of human lung adenocarcinoma (L2987) implanted in athymic mice.
"
Related Drugs and Biologics
1.
Doxorubicin (Adriamycin)
2.
BR96-doxorubicin immunoconjugate
3.
Immunoconjugates (Immunoconjugate)
4.
Antigens